Publications and Announcements. Except as otherwise permitted under this Agreement or as required by law, regulation, or court order, each Party agrees not to publish any Confidential Information received from the other Party. Except as required by law, regulation or court order, each Party agrees that, without obtaining the other Party's prior written approval for any publication or any presentation, which shall not be unreasonably withheld, such Party shall not publish or present (i) any Confidential Information generated by either Party related to the development or commercialization of Licensed Product, or (ii) the results of any clinical trial studies or non-clinical studies or investigations carried out by either Party related to the development of Licensed Product. At least sixty (60) days prior to any such publication or presentation, the Party seeking to publish such information (the "Publishing Party") shall provide the other Party with a copy of the proposed abstract, manuscript or presentation (including, without limitation information to be presented verbally) for review. The other Party shall respond in writing to the Publishing Party within such time period with either approval of the proposed material or a specific statement of (a) concern based upon the need to seek patent protection, (b) concern regarding competitive disadvantage arising from the proposal, or (c) concern regarding the timing and circumstances of such disclosure in light of the other Party's business. In the event that the other Party has concerns about disclosure of Confidential Information, the Publishing Party agrees to provide the other Party with any additional information relating to the proposed disclosure, as reasonably requested. In the event of concern relating to patent protection, the Publishing Party agrees not to submit such abstract or manuscript for publication or to make such presentation until the other Party has had a reasonable period of time to seek patent protection for any material in such publication or presentation which it believes is patentable or to resolve any other issues, such period not to exceed sixty (60) additional days. In the event of concern regarding competitive disadvantage or the timing and other circumstances relevant to the disclosure, the Parties will negotiate in good faith to attempt to arrive at a compromise to permit the Publishing Party an opportunity to publish or present the disclosure within a reasonable period of time. The Publishing Party also agrees ...
Publications and Announcements. Consultant agrees not to publish any Confidential Information without INTERCEPT’s consent, and agrees not to publish any information related to an Invention not already protected by a Patent Rights without the consent of INTERCEPT.
Publications and Announcements. 11.1 Except as required by law, regulation, or any competent government authority or Regulatory Authority or in compliance with this Section 11, the Parties shall consult on and agree in writing upon the form of all press releases, publications, public announcements and public disclosures concerning the Supply Agreement or its subject matter (each a “Publication”).
11.2 Neither Party shall use the names, logos or trademarks of the other in any Publication, advertising, promotion, or commercially-related publicity without the named Party’s prior express written consent, except as expressly provided for in this Section 11.
11.3 Notwithstanding the foregoing, the Customer may issue a Publication regarding Customer Vaccine / Customer Product at any time provided that such Publication does not include any Confidential Information of Dynavax.
Publications and Announcements. During the term of this Agreement, TES shall submit to INTERCEPT for review and approval all proposed academic, scientific and medical publications, and public presentations relating to the Research Program. INTERCEPT shall respond in writing within 90 days with either approval of the proposed material or a specific statement of (a) concern based upon the need to seek patent protection, (b) concern regarding competitive disadvantage arising from the proposal, or (c) concern regarding the timing and circumstances of such disclosure in light of INTERCEPT’s business. In the event that INTERCEPT has concerns about the disclosure of Inventions or Confidential Information, TES agrees to provide INTERCEPT with any additional information relating to the proposed disclosure. Notwithstanding the above, TES agrees not to publish or disclose any Inventions or Confidential Information without INTERCEPT’s formal consent.
Publications and Announcements. No Party shall make a public announcement or issue a press release about this Agreement, the transactions set forth herein, the terms and conditions of this Agreement, or the Party’s relationship without the prior written consent of the other Party. Each Party shall coordinate with the other Party with respect to, and provide advance copies to such other Party for review of, the text of any proposed announcement or publication that may include any non-public information concerning this Agreement or the activities or obligations of any Party hereunder prior to the dissemination thereof to the public or to any Person other than such announcing Party’s employees, contractors, subcontractors, representatives, agents or Affiliates, in each case, who agree in writing to keep such information confidential. The non-announcing Party shall deliver written notice to the announcing Party of any objections to the proposed announcement or publication within a reasonable period of time after receiving the advance copy of the proposed announcement; provided, however, the non-announcing Party’s failure to notify the announcing Party of any objections shall not be construed as a waiver of the covenant set forth in the first sentence of this Section 15.2.
Publications and Announcements. 11.1 The Grantors acknowledge the Organisation’s need to publish details of the results of the Project in learned journals and to present such results at academic conferences. So as not to jeopardise any Project patent filing or exploitation being carried out by the Exploiting Party (in any case where the Exploiting Party is not the Organisation), the Organisation shall procure that the Principal Investigator furnishes the Exploiting Party [and the IPMG] with copies of any proposed publication or presentation which relates to any Project Intellectual Property in advance of the submission of such proposed publication or presentation to a journal, editor or publication. The Exploiting Party and the IPMG shall have twenty (20) Business Days from and including the date of receipt from the Organisation of any proposed publication or presentation to object to the same because there is patentable subject matter relating to a Project Invention that needs protection or such publication would materially jeopardise any exploitation activity. The Exploiting Party shall not seek to withhold consent where such publication or presentation will not prejudice the protection or exploitation of the Project Intellectual Property.
11.2 If the Exploiting Party [or the IPMG] object to any such publication or presentation on the basis that it would disclose patentable information, the Organisation shall refrain (and shall procure that the Principal Investigator and the Staff also refrain) from making such publication or presentation for a period of forty (40) Business Days from the date of receipt of such objection in order for the Exploiting Party to file the relevant patent application(s) with respect to the patentable subject matter contained in the proposed publication or presentation.
11.3 A copy of the final manuscript of all research publications that relate to the Project must be deposited into PubMed Central (or Europe PubMed Central) upon acceptance for publication, to be made freely available as soon as possible and in any event no later than six (6) months after the journal publisher’s official date of final publication.
11.4 Save as required by law or any competent regulatory authority, no announcement concerning this Agreement or its subject matter shall be made by the Organisation without the prior written approval of the Grantors. For the avoidance of doubt the Organisation and the Principal Investigator must consult with the Grantors (and the relevant media offic...
Publications and Announcements. No Party shall make a public announcement or issue a press release about this Agreement, the transactions set forth herein, the terms and conditions of this Agreement, or the Party's relationship without the prior written consent of the other Party. Each Party shall coordinate with the other Party with respect to, and provide advance copies to such other Party for review of, the text of any proposed announcement or publication that may include any non-public information concerning this Agreement or the activities or obligations of any Party hereunder prior to the dissemination thereof to the public or to any Person other than such announcing Party's employees, contractors, subcontractors, representatives, agents or Affiliates, in each case, who agree in writing to keep such information confidential. The non-announcing Party shall deliver written notice to the announcing Party of any objections to the proposed announcement or
Publications and Announcements. 9.2.1. The Parties shall consult with each other about form, content and timing of any voluntary statements or announcements concerning this Agreement, its conclusion and its performance prior to their initial publication or announcement, as applicable. No Party shall without such consultation publish or otherwise make any voluntary statement or announcement, unless such Party has previously complied with this Section 9.2 with respect to such voluntary statement or announcement.
9.2.2. To the extent publications, announcements or filings are required by securities or other Laws or rules or are ordered by a competent court or a competent public authority, the Parties shall endeavour prior notice. If prior notice is not or not reasonably possible, the Party concerned shall inform the respective other Party about the publication, announcement or filing as soon as is reasonably practicable.
Publications and Announcements. 5.1. A Party may make a publication or presentation (including but not limited to media or advertising) based on, or referring to the Licensed IP subject to not disclosing any Confidential Information of the other Party. The publication or presentation will acknowledge that the IP was developed at the University.
5.2. No media statement or announcement concerning this Agreement shall be made unless approved by both Parties or is required by law.
Publications and Announcements. Except as otherwise permitted under any of the Transaction Documents or as required by law, regulation, or court order, each Party agrees not to publish any Confidential Information received from the other Party. Except as required by law, regulation or court order, Medeva and TGC each agree that without obtaining the other Party's prior written approval for any publication or any presentation, which shall not be unreasonably withheld, neither Party shall publish or present (i) any Confidential Information generated by that Party and related to the development or commercialization of Licensed Products for use in the Field, or (ii) the results of any clinical trial studies or non-clinical studies or investigations carried out by that Party related to the development of Licensed Products for use in the Field. At least thirty (30) days prior to any such publication or presentation, the Party proposing to publish or present shall provide the other Party a copy of the proposed abstract, manuscript or presentation (including without limitation information to be presented verbally) for review. The other Party shall respond in writing within such time period with either approval of the proposed material or a specific statement of (a) concern based upon the need to seek patent protection, (b) concern regarding competitive disadvantage arising from the proposal, or (c) concern regarding the timing and circumstances of such disclosure in light of such Party's
